交易中 01-30 10:13:22 美东时间
-0.415
-0.33%
华盛资讯1月29日讯,Stifel金融公布2025财年Q4业绩,公司Q4营收15.61亿美元,同比增长14.4%,归母净利润2.55亿美元,同比增长8.7%。
01-29 03:04
Stifel Reports Q4 Net Revenues of USD 1.56 Billion, Up 15% Stifel Financial Corp. reported record full year results for the period ended December 31, 2025. Net revenues for the fourth quarter (Q4) reached USD 1.56 billion. Net income attributable to shareholders for Q4 was USD 255.0 million, or USD
01-28 20:02
Companies Reporting Before The Bell • VF (NYSE:VFC) is estimated to report quar...
01-28 19:11
Stifel Financial Corp. (NYSE:SF) today announced that its Board of Directors declared a three-for-two stock split of Stifel's common stock in the form of a 50% stock dividend to be distributed on February 26, 2026, to
01-28 19:05
Stifel Financial Announces Three-for-Two Stock Split Stifel Financial Corporation has announced a three-for-two stock split of its common stock, to be distributed on February 26, 2026. Following the split, the company will have approximately 155 million shares outstanding, up from about 103 million
01-28 06:00
1919 Investment Counsel Adds Senior Portfolio Managers in New York 1919 Investment Counsel, a Stifel Subsidiary, Expands New York Portfolio Management Team with Key Hires Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strive
01-21 22:30
Stifel Financial Corp. (NYSE: SF) will release its Q4 & full year 2025 financial results before the market opens on January 28, 2026. A conference call to review the results will be held at 9:30 a.m. Eastern Time that day. Interested parties can join by dialing (800) 330-6710 (participant ID 7359166) or via a live audio webcast on Stifel’s website, www.stifel.com. A replay will be available approximately one hour after the call. Stifel is a diver...
01-21 21:30
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
今日重点评级关注:HC Wainwright & Co.:维持Enlivex Therapeutics"买入"评级,目标价从7美元升至13美元;BTIG:维持Oruka Therapeutics"买入"评级,目标价从63美元升至73美元
01-13 10:18
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22